The effect of androgen deprivation on malignant and benign prostate tissue

Medical Oncology

Volumn 14, Issue 3-4, 1997, Pages 145-152

  Guinan, Patrick ^a   Didomenico, David ^b   Brown, James ^b   Shaw, Michael ^b   Sharifi, Roohollah ^b   Ray, Veronica ^b   Shott, Susan ^b   Rubenstein, Marvin ^b  

^a Hektoen Institute for Medical Research   (United States)

^b NONE

Author keywords

Androgen deprivation; bcl 2; Prostate cancer; PSA

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CELL VACUOLE; CLINICAL ARTICLE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SQUAMOUS CELL METAPLASIA;

EID: 0031469637     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02989642     Document Type: Article

References (24)

1. Soloway, M., Sharifi, R., Wajsman, Z., McLeod, D., Wood, Jr. D.P., Puras-Baez, A., the investigators of the LUPRON depot neoadjuvant prostate cancer study group. (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. J. Urol. 154, 424-8.
2. Pilepich, M.V., Sause, W., Shipley W. et al. (1995) Androgen deprivation with radiation therapy. Urology 45, 616-23.
3. Mostofi, F., Sesterhenn, I. and Sabin, L. (1980) Histologic typing of prostate tumors. International histological classification of tumors. No.22 Geneva World Health Organization.
4. van de Voorde, W.M., Elgamal, A.A., Van Poppel, H.P., Verbeken, E.K., Baert, L.V. and Lauweryns, J.M. (1994) Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomy. Cancer 74, 3164-75.
5. Kennedy, T.J., Sonneland, A.M., Marlett, M.M. and Troup, R.H. (1992) Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J. Urol. 147, 891-3.
6. Macfarlane, M.T., Abi-Aad, A., Stein, A., Danella, J., Belldegrun, A. and deKernion, J.B. (1993) Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J. Urol. 150, 132-4.
7. Stamey, T. and McNeal, J. (1992) Adenocarcinoma of the Prostate, In P. Walsh, A. Retick, T. Stamey and E. Vaught (eds) Campell's Urology, pp. 1159-1221. Philadelphia: WB Saunders Co.
8. Têtu, B., Srigley, J.R., Boivin, J.-C., Dupont, A., Monfette, G., Pinault, S. et al. (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am. J. Surg. Pathol. 15, 111-20.
9. Berner, A., Nesland, J.M., Waehre, H., Silde, J. and Fossa, S.D. (1993) Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. Br. J. Canc. 68, 380-4.
10. Fair, W.R., Aprikian, A., Sogani, P., Reuter, V. and Whitmore, Jr, W.F. The role of neoadjuvant hormonal manipulation in localized prostate cancer. Cancer 71(3 suppl), 1031-8.
11. Wright, G.L., Haley, C., Beckett, M.L. and Schellhammer, P.F. (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissue. Urol. Oncol. 1, 18-28.
12. Masai, M., Sumiya, H., Akimoto, S., Yatani, R., Chang, C., Liao, S. and Shimazaki, J. (1990) Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. The Prostate 17, 293-300.
13. van der Kwast, T.H., Schalken, J., Ruizeveld de Winter, J.A., van Vroonhoven Cor, C.J., Mulder, E., Boersma, W. and Trapman, J. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J. Canc. 48, 189-93.
14. Steiner, M. and Barrack, E. (1990) Expression of transforming growths (TGF-α and TGF-β) and epidermal growth factor (EGF) in normal and malignant rat prostate. J. Urol. 143, 240a.
15. Galluzzi, C.M., Montironi, R., Giannulis, I., Diamanti, L. and Scarpelli, M. (1993) Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Path. Res. Pract. 189, 1154-60.
16. Armas, O.A., Aprikian, A.G., Melamed, J., Cohen, D., Cordon-Cardo, C., Fair, W.R. et al. (1993) Clinical and pathobiological effects of total androgen ablation on clinically localized prostatic carcinoma. J. Urol. 149, 347a.
17. Gleave, M.E., Goldengerg, S.L., Jones, E.C., Bruchovsky, N. and Sullivan, L.D. (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol. 155, 213-9.
18. Navone, N.M., Troncoso, P., Pisters, L.L, Goodrow, T.L., Palmer, J.L., Nichols, W.W., von Eschenbach, A.C. and Conti, C.J. (1993) p53 protein accumulation and gene mutation in the progression of human prostate cancer. JNCI 85, 1657-99.
19. Hamdy, F.C., Thurrell, W., Lawry, J., Anderson, J.B., Parsons, M.A., Rees, R.C. and Royds, J. (1993) P53 mutant expression in human prostatic adenocarcinoma. J. Urol. 149, 377a.
20. Zhang, X., Colombel, M., Raffo, A. and Buttyan, R. (1994) Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. Biochim. Biophys. Res. Commun. 189, 1189-94.
21. Heidenberg, H.B., Sesterhenn, I.A., Gaddipati, J.P., Weghorst, C.M., Buzard, G.S., Moul, J.W. and Srivastava, S. (1983) Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154, 414-21.
22. Murphy, W.M., Soloway, M.S. and Barrows, G.H. (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68, 821-28.
23. Hellström, M., Häggman, M., Brändstedt, S., de la Torre, M., Pedersen, K., Jarsfeldt, J. et al. (1993) Histopathological changes in androgen-deprived localized prostatic cancer. Eur. Urol. 24, 461-5.
24. Smith, D.A. and Murphy, W.M. (1994) Histologic changes in prostate carcinomas treated with Leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73, 1472-7.